Lupin Pharma

As per the USFDA, the companies are recalling the product due to deviation from the current good manufacturing practices

Updated On: 26 Jul 2020 | 3:26 PM IST

The specified batch, which is being recalled, has been manufactured at Unichem's Goa-based facility

Updated On: 21 Jun 2020 | 1:30 PM IST

Go ahead for inhaler launch in the US and resolution of plant compliance issues are other triggers

Updated On: 30 May 2020 | 3:59 PM IST

Brokerage firm Prabhudas Lilladher has upgraded Lupin's stock to 'Buy' from earlier 'Reduce' with target price of Rs 978

Updated On: 14 May 2020 | 1:04 PM IST

The inspection at the facility was carried out by the US Food and Drug Administration between November 26, 2018

Updated On: 15 Apr 2020 | 12:21 PM IST

The stock of the drug maker has rallied 47 per cent in the past six trading days, and was quoting close to its 52-week high level of Rs 882

Updated On: 15 Apr 2020 | 11:01 AM IST

The recent gains came on Monday after the company received the USFDA approval for its Nagpur facility

Updated On: 15 Apr 2020 | 3:07 AM IST

The company's shares surged 4.14% to Rs 820.40 after they received the inspection report (EIR) from the US drug regulator

Updated On: 13 Apr 2020 | 12:55 PM IST

Cipla gets nod for drug from USFDA earlier than expected; Lupin in fray

Updated On: 10 Apr 2020 | 2:05 AM IST

The near-term worry for the company is the ongoing investigation by the US Department of Justice related to price fixing and cartelisation by generic companies

Updated On: 12 Mar 2020 | 2:09 AM IST

The United States Food and Drug Administration (USFDA) carried out the inspection of the company's Vizag API manufacturing facility between January 13, 2020 and January 17, 2020.

Updated On: 20 Feb 2020 | 10:25 AM IST

High costs have hit Q3 margins, while multiple one-offs have impacted firm's bottom line

Updated On: 20 Feb 2020 | 10:11 AM IST

The USFDA issues observations by means of Form 483 notifying a company's management of objectionable conditions at the facility inspected

Updated On: 11 Jan 2020 | 11:19 PM IST

The Mumbai-based company's product is the generic version of Taro Pharmaceuticals Inc's Topicort Ointment.

Updated On: 20 Dec 2019 | 4:03 PM IST

The product is a generic version of Novartis Pharmaceuticals Corporation's Myfortic delayed-release tablets in the same strengths, it added

Updated On: 19 Dec 2019 | 10:25 PM IST

Last month, Lupin's board had approved the stake sale in Kyowa

Updated On: 17 Dec 2019 | 6:44 PM IST

Trading calls by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers

Updated On: 22 Nov 2019 | 7:40 AM IST

The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India

Updated On: 11 Nov 2019 | 11:29 PM IST

The medicine is indicated for prophylaxis and treatment of chronic asthma in adults and children 12 years of age and older, it added.

Updated On: 08 Nov 2019 | 7:53 PM IST

While pricing pressure in the US generics market remains in low single digits, large product approvals are crucial to boost sales

Updated On: 07 Nov 2019 | 12:54 AM IST